Is sirolimus covered by medical insurance?

Sirolimus (sirolimus) can effectively prevent kidney transplant rejection in patients with low to moderate rejection risk. It is also currently approved for the treatment of lymphangioleiomyomatosis (S-LAM). Sirolimus’s impact on lung function is considered important. Many clinical studies have proven that the benefits of sirolimus outweigh its risks and it can be authorized for use. The active substance in sirolimus is an immunosuppressant (a drug that reduces the activity of the immune system).

In the body, sirolimus attaches to a protein inside cells, forming a "complex." This complex then blocks another protein called the mammalian target of rapamycin (mTOR). Because mTOR is involved in the proliferation of activated T lymphocytes (white blood cells responsible for attacking transplanted organs), sirolimus reduces the number of these cells, thereby reducing the risk of organ rejection. In lymphangioleiomyomatosis (S-LAM), mTOR is overactive, leading to excessive proliferation of cells that contribute to the disease. By blocking mTOR, sirolimus reduces the proliferation of these cells.

SirolimusThe original drug has been launched in China and has entered the scope of Class B medical insurance. SpecificationsThe price of each box of 1mg*10 tablets is about 400 yuan. Domestic drugs are only available for patients with anti-rejection reactions in organ transplantation. Patients who do not meet the conditions may not be able to purchase this drug. The reimbursement ratios are different in different regions, and the prices after reimbursement are also different. The original sirolimus drug has also been launched overseas. The price of the Turkish version of Specifications1mg*100 tablets per box is around RMB 2,000 (the price may fluctuate due to exchange rates). The ingredients of the original drugs marketed in China are basically the same as those of foreign original drugs. Currently, there are no generic sirolimus drugs produced in other countries.